Orchestra BioMed将因美国血液技术收购Vivasure获得最高2100万美元收益

美股速递
Jan 12

美国血液技术(Haemonetics)对Vivasure的收购案,将为Orchestra BioMed带来最高达2100万美元的资金流入。这一交易预计显著增强Orchestra BioMed的现金流状况,为其后续业务拓展提供重要支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10